Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

NCT07479797 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT07479797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07479797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
Lead sponsor
Kite, A Gilead Company
Phase
Phase 3
Overall status
Recruiting
Start date
May 22, 2026
Completion date
May 31, 2031
Enrollment
550 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory large b-cell lymphoma